Introduction Conventional surgery is the treatment of choice for severe mitral valve regurgitation. However, it is not feasible for patients at high surgical risk, who have high morbidity and mortality rates despite clinical treatment. Percutaneous valve treatment (MitraClip) has been evolving as a therapeutic perspective for this population, with reduced heart failure (HF) hospitalization and all-cause mortality rates.,, Three-dimensional transesophageal echocardiography (3DTEE) has an additive role during clinical follow-up, especially in cases of suspected late complications with high detail of […]